Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: A single center experience

Basit Öğe Kaydı
dc.contributor.authorArduç, Ayşe
dc.contributor.authorGökay, Ferhat
dc.contributor.authorIşık, Serhat
dc.contributor.authorÖzu?uz, Ufuk
dc.contributor.authorAkbaba, Gülhan
dc.contributor.authorAteş Tütüncü, Yasemin
dc.contributor.authorBerker, Dilek
dc.contributor.authorKüçükler, Ferit Kerim
dc.contributor.authorAydın, Yusuf
dc.contributor.authorGüler, Serdar
dc.date.accessioned2019-05-13T08:57:30Z
dc.date.available2019-05-13T08:57:30Z
dc.date.issued2015
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractIntroduction: Patients with hyperprolactinemia who require medical therapy are typically treated with dopamine agonists (DAs). In most cases, DAs normalize prolactin levels, control symptoms, and substantially decrease tumor size. Here, we aimed to compare the efficacy of cabergoline (CAB) and bromocriptine (BRC) in patients with hyperprolactinemia at a single center. Methods: Retrospective analysis of the clinical records of 498 patients with hyperprolactinemia [mean age 33.3 ± 10.8 years (range 16-66), 450 women, and 48 men] who had received either CAB (n = 450) or BRC (n = 48) was performed. Results: The mean age, gender distribution, and treatment duration were similar between the CAB and BRC groups (33.2 ± 11 vs. 34.1 ± 9.6 years, male/female 44/406 vs. 4/44, 18.7 ± 12.1 vs. 17.8 ± 6.0 months, respectively; p > 0.05 for all). Mean dosage was 1.5 ± 1.6 mg/week for CAB and 3.8 ± 2.7 mg/day for BRC. Baseline prolactin levels, frequency of galactorrhea, amenorrhea, oligomenorrhea, erectile dysfunction, infertility, and visual impairment were similar between the two groups, whereas the baseline tumor volume was higher in the CAB group. The prolactin normalization rate (87.4 vs. 41.4 %, p = 0.029) and tumor volume shrinkage (79.8 ± 39.1 vs. 54.1 ± 55.3 %, p = 0.015) were significantly higher in the CAB-treated patients than in the BRC-treated patients, while the tumor cure rates were similar. Symptom relief was higher in the CAB group than in the BRC group. More side effects were recorded in patients who took BRC (29.1 vs. 5.3 %, p < 0.001). Conclusion: Our data revealed that CAB was more effective than BRC in controlling symptoms associated with hormone excess, normalizing serum prolactin levels, and shrinking prolactinomas. © 2014 Italian Society of Endocrinology (SIE).
dc.identifier.citationArduç, A., Gökay, F., Işık, S., Özuğuz, U., Akbaba, G., Ateş Tütüncü, Y., Berker, D., Küçükler, F. K. [et.al.]. (2015). Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience. Journal of Endocrinological Investigation, 38(4), 447-453.
dc.identifier.doi10.1007/s40618-014-0212-4
dc.identifier.endpage453en_US
dc.identifier.issn0391-4097
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ1
dc.identifier.startpage447en_US
dc.identifier.urihttps://doi.org/10.1007/s40618-014-0212-4
dc.identifier.urihttps://hdl.handle.net/11491/944
dc.identifier.volume38en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSpringer International Publishing
dc.relation.ispartofJournal of Endocrinological Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBromocriptineen_US
dc.subjectCabergolineen_US
dc.subjectDopamine Agonistsen_US
dc.subjectHyperprolactinemiaen_US
dc.titleRetrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: A single center experience
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu